NJ Pharma Co. Revives Lupus Product Row With FDA
A New Jersey pharmaceutical firm has accused the U.S. Food & Drug Administration of reneging on a promise to relax threats to seize a lupus product after the two sides sparred...To view the full article, register now.
Already a subscriber? Click here to view full article